What CBN Can (and Cannot) Do: The Evidence Beyond CBD

Cannabinol, or CBN, is often marketed as the cannabis compound most likely to promote sleep. The research is more measured. A 2026 randomized, placebo-controlled trial in 20 adults with diagnosed insomnia found that a single 300-milligram dose improved some measures of sleep, including sleep-onset time, subjective sleep quality, and time spent in one stage of non-rapid-eye-movement sleep. However, it did not significantly reduce the study’s primary outcome: wakefulness after sleep onset. The smaller 30-milligram dose did not produce significant improvements, and the researchers called for larger, longer studies.

That result adds to a still limited body of evidence. CBN may have therapeutic potential, particularly in sleep-related products, but it is not yet an established treatment for insomnia, anxiety, cancer, glaucoma, or other medical conditions.

What CBN is

CBN is a naturally occurring phytocannabinoid produced primarily as THC breaks down through oxidation during aging and storage. It is not simply an older version of CBD, and the two compounds are not interchangeable. CBD is abundant in some cannabis and hemp varieties, while CBN is usually present in much smaller amounts unless the plant material has undergone substantial chemical degradation.

CBN interacts relatively weakly with the CB1 and CB2 receptors of the endocannabinoid system. Its effects may also involve other biological targets, and researchers are still working to determine how its activity, metabolites, dose, and formulation influence the body.

Does CBN act as a sedative?

The popular image of CBN as “the sleepy cannabinoid” comes partly from the observation that older cannabis can contain more CBN. Early laboratory and human studies offered hints of sedation, especially when CBN was combined with THC, but they did not establish that CBN alone is a powerful sleep aid.

A 2023 double-blind, placebo-controlled study gave participants 20 milligrams of CBN, either alone or with different amounts of CBD, for seven nights. The CBN-only group reported fewer nighttime awakenings and less overall sleep disturbance than the placebo group. Its improvement in overall sleep quality, however, did not reach conventional statistical significance, and adding CBD did not enhance the effect. The study used self-reported measures and enrolled adults with poor sleep rather than people with clinically diagnosed insomnia. The published trial report therefore supports cautious interest, not a definitive conclusion.

The 2026 insomnia trial used overnight polysomnography, a more objective method of measuring sleep. Its findings were mixed: 300 milligrams of CBN improved several secondary measures, but neither dose significantly reduced wake time after sleep onset. The study included only 20 people and examined a single night of treatment, so its results cannot establish long-term effectiveness or safety.

Other proposed benefits

Some of the most frequently cited CBN findings come from animal or laboratory research.

• Appetite: In a 2012 study, oral CBN increased feeding behavior in satiated male rats, while CBD reduced food intake. The effect was linked to CB1-receptor activity. These results may justify further research into appetite stimulation, but they do not show that CBN improves appetite in people. See the original rat-feeding study.
• Cancer: A 1975 study found that CBN slowed the growth of Lewis lung adenocarcinoma in mice and prolonged survival at some doses. This was preclinical research, not a human cancer treatment trial. It does not demonstrate that CBN treats lung cancer or works synergistically with modern cancer medicines. The original antineoplastic study examined cannabinoids in mice and isolated cells.
• Glaucoma: In a 1984 experiment, chronic CBN administration lowered intraocular pressure in cats. The study also reported ocular and neurological toxicity. Results in cats cannot be assumed to predict benefits or risks in humans, and CBN is not an established glaucoma therapy. See the original eye-pressure study.

These findings illustrate the distance between a biological signal and a clinically useful medicine. Cell cultures and animal models can help identify possible mechanisms, but they do not establish the appropriate human dose, effectiveness, interactions, or long-term safety.

CBN compared with CBD

CBD generally does not produce the intoxicating effects associated with THC, although it can cause drowsiness and interact with other medicines. CBN has relatively weak activity at cannabinoid receptors, and human studies have not consistently shown the classic cannabis-like effects associated with THC. Calling CBN entirely non-psychoactive or universally sedating is therefore too broad.

Potential side effects may include sleepiness, dizziness, impaired alertness, dry mouth, or changes in appetite. The available human safety data remain limited, especially for high doses, prolonged use, older adults, pregnant or breastfeeding people, and anyone taking medicines that affect the central nervous system. Products that combine CBN with THC or other sedating substances may present additional risks.

What the law means for CBN products

The 2018 Farm Bill removed hemp and hemp-derived materials containing no more than 0.3 percent delta-9 THC from the federal definition of marijuana. That does not mean every CBN product is automatically lawful. The Drug Enforcement Administration explains that hemp-derived status matters, while cannabinoids found in material meeting the federal definition of marijuana remain subject to the Controlled Substances Act. State laws can impose additional restrictions.

The Food and Drug Administration also retains authority over cannabis-derived products sold as foods, supplements, or drugs. A product marketed with claims that it treats insomnia, anxiety, cancer, glaucoma, or another disease may be regulated as a drug, and CBN products sold over the counter have not undergone FDA approval for those uses.

The bottom line

CBN is a scientifically interesting minor cannabinoid, but the strongest claims surrounding it still run ahead of the evidence. Early animal studies suggest possible effects on appetite, tumor growth, and eye pressure, while human sleep research now offers a preliminary but inconsistent signal. Larger clinical trials using standardized products, objective sleep measurements, clinically meaningful outcomes, and longer follow-up are needed before CBN can be considered a proven therapy.